Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A prospective, randomized, double-blind placebo-controlled dose-finding study of different regimens of mannan-conjugated allergoids of birch pollen allergens administered subcutaneously to patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis

Next Previous
Trial Profile

A prospective, randomized, double-blind placebo-controlled dose-finding study of different regimens of mannan-conjugated allergoids of birch pollen allergens administered subcutaneously to patients with birch pollen-induced allergic rhinitis or rhinoconjunctivitis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs T 502 (Primary)
  • Indications Allergic rhinitis; Allergic rhinoconjunctivitis
  • Focus First in man; Therapeutic Use
  • Sponsors Immunotek SL

Most Recent Events

  • 27 Feb 2023 Results assessing Immunological parameters analyzed before and after treatment with either T502 or placebo in two double-blind, placebo-controlled trials and 1 subsequent open follow-up study presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 27 Feb 2023 Trial design and clinical development of T502 from three clinical studies presented at the 2023 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
  • 09 Sep 2019 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top